companies pinning hopes alzheimer treatments base inhibitor mechanism including eli lilly co biogen novartis collaboration amgen inc. lilly previously endured multiple failures solanezumab targets beta amyloid different way recent setback lilly said drug failed slow declines mental capacity patients mild symptoms researchers increasingly focusing attacking disease earlier appears likely symptoms taken hold current approaches fail work merck said study drug patients prodromal alzheimer disease continue results expected february 2019 patients prodromal alzheimer disease objective memory problems relatively normal functioning activities daily living blinded clinical trials use independent monitors watch unexpected safety problems crop recommend stopping study early clear drug going